MSF Field Research > 1 Published Research and Commentary > Vaccination > Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/221031
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
Barnes Avidity of serogroup A meningococcal - Scand J Immunol.pdf781KbAdobe PDF

Title: Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine
Authors: Bårnes, G K
Naess, L M
Rosenqvist, E
Guerin, P J
Caugant, D A
Affiliation: Department of Bacteriology and Immunology, Norwegian Institute of Public Health, Oslo, Norway; Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Oslo, Norway; Epicentre, Paris, France; Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, CCVTM, Oxford, UK; Department of International Health, University of Oslo, Oslo, Norway
Citation: Scand J Immunol 2011; 74:87-94
Publisher: Blackwell
Journal: Scandinavian Journal of Immunology
Issue Date: 8-Jun-2011
URI: http://hdl.handle.net/10144/221031
DOI: 10.1111/j.1365-3083.2011.02535.x
PubMed ID: 21332570
Additional Links: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2011.02535.x/abstract
Abstract: In the absence of an affordable conjugate meningococcal vaccine, mass vaccination campaigns with polysaccharide vaccines are the means to control meningitis epidemics in sub-Saharan Africa. Facing global vaccine shortage, the use of reduced doses, which have been shown to be protective by serum bactericidal activity, can save many lives. In this study, we investigated the antibody responses and avidity of IgG antibodies evoked against the serogroup A capsule of Neisseria meningitidis by different doses of an A/C/Y/W135 polysaccharide vaccine. Volunteers in Uganda were vaccinated with 1/10, 1/5 or a full dose (50 μg) and revaccinated with a full dose after 1 year. Specific IgG geometric mean concentrations and geometric mean avidity indices (GMAI) were determined by a modified enzyme-linked immunosorbent assay (ELISA) using thiocyanate as a chaotropic agent. After vaccination with 1/10 or 1/5 doses, the GMAI increased from 1 month to 1 year. One year following the initial dose, the GMAI levels were higher in the arm receiving reduced doses than for the arm receiving a full dose. Following the second full dose, avidity indices equalized at approximately the same level in the three arms. Although there are practical challenges to the use of reduced doses in the field, our findings suggest that reduced doses of polysaccharide vaccine are able to elicit antibodies of as good avidity against serogroup A polysaccharide as a full dose.
Type: Article
Language: en
MeSH: Adolescent
Antibodies, Bacterial
Antibody Affinity
Child
Child, Preschool
Humans
Immunoglobulin G
Meningococcal Vaccines
Neisseria meningitidis, Serogroup A
Randomized Controlled Trials as Topic
Uganda
Vaccination
Young Adult
ISSN: 1365-3083
Rights: Archived with thanks to Blackwell and the Scandinavian Journal of Immunology
Appears in topics: Vaccination

Related articles on PubMed
bullet
Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda.
Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, Nabasumba C, Borrow R, Frøholm LO, Ghabri S, Batwala V, Twesigye R, Aaberge IS, Røttingen JA, Piola P, Caugant DA
2008
bullet
bullet
bullet
bullet
See all 101 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository | Cookies

My MSF

MSF logo MSF Field Research

Jul 31, 2014